Pfizer cardiovascular unbranded
With the launch of Bococizumab, Pfizer was once again, entering the highly competitive high cholesterol treatment market. In preparation, we developed an unbranded campaign to be used at the ESC Congress. To ensure success, it was necessary to optimize this campaign so that it is powerful enough to cut through the clutter, build positive brand awareness, and, ultimately, motivate target HCPs to consider their novel CV drug.